MSLE and MSCLF Related Headlines

Go Back

Feb 12, 2026 07:00AM Satellos begins phase 2 trial of SAT-3247 for duchenne muscular dystrophy

Feb 12, 2026 07:00AM Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy

MSLE and MSCLF Related Press Releases

Go Back

Feb 12, 2026 07:00AM Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy

MSLE and MSCLF Related SEC Filings

Go Back

May 12, 2026 04:24PM Form SCHEDULE 13G Satellos Bioscience Inc. Filed by: Qiming U.S. Healthcare Fund III, L.P.

Apr 9, 2026 07:00AM Form 6-K Satellos Bioscience Inc. For: Apr 09

Mar 27, 2026 08:36AM Form S-8 Satellos Bioscience Inc.

Mar 27, 2026 08:24AM Form 40-F Satellos Bioscience Inc. For: Dec 31

Mar 27, 2026 07:00AM Form 6-K Satellos Bioscience Inc. For: Mar 27

Mar 10, 2026 07:00AM Form 6-K Satellos Bioscience Inc. For: Mar 10

Feb 24, 2026 07:15AM Form 6-K Satellos Bioscience Inc. For: Feb 24

Feb 19, 2026 11:05AM Form 6-K Satellos Bioscience Inc. For: Feb 19

Feb 18, 2026 02:03PM Form 6-K Satellos Bioscience Inc. For: Feb 18

Feb 17, 2026 03:23PM Form 6-K Satellos Bioscience Inc. For: Feb 17

Feb 12, 2026 07:15AM Form 6-K Satellos Bioscience Inc. For: Feb 10

Feb 10, 2026 07:15AM Form 6-K Satellos Bioscience Inc. For: Feb 10

Feb 10, 2026 06:03AM Form 6-K Satellos Bioscience Inc. For: Feb 09